CO6270300A2 - Suspension pediatrica estabilizada de carisbamato - Google Patents

Suspension pediatrica estabilizada de carisbamato

Info

Publication number
CO6270300A2
CO6270300A2 CO10055401A CO10055401A CO6270300A2 CO 6270300 A2 CO6270300 A2 CO 6270300A2 CO 10055401 A CO10055401 A CO 10055401A CO 10055401 A CO10055401 A CO 10055401A CO 6270300 A2 CO6270300 A2 CO 6270300A2
Authority
CO
Colombia
Prior art keywords
stabilized
carisbamato
suspension
pediatric
pediatric suspension
Prior art date
Application number
CO10055401A
Other languages
English (en)
Inventor
Roger EMBRECHTS
Leersnijder Cedric De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40386492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6270300(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO6270300A2 publication Critical patent/CO6270300A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion provee una suspension farmacéutica estabilizada de carisbamato para uso pediatrico y en adultos. Mas en particular, la suspension se estabiliza con hipromelosa (HPMC) para evitar el crecimiento de cristales de las particulas suspendidas y para evitar la recristalizacion del producto farmacologico con cambio a la forma polimorfica.
CO10055401A 2007-10-31 2010-05-10 Suspension pediatrica estabilizada de carisbamato CO6270300A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98414407P 2007-10-31 2007-10-31

Publications (1)

Publication Number Publication Date
CO6270300A2 true CO6270300A2 (es) 2011-04-20

Family

ID=40386492

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10055401A CO6270300A2 (es) 2007-10-31 2010-05-10 Suspension pediatrica estabilizada de carisbamato

Country Status (26)

Country Link
US (4) US8263652B2 (es)
EP (1) EP2214637B1 (es)
JP (3) JP5841333B2 (es)
KR (1) KR101568681B1 (es)
CN (2) CN101848699A (es)
AR (1) AR069125A1 (es)
AU (1) AU2008320458B2 (es)
BR (1) BRPI0818118B8 (es)
CA (1) CA2703971C (es)
CL (1) CL2008003261A1 (es)
CO (1) CO6270300A2 (es)
CR (1) CR11550A (es)
EA (1) EA019881B1 (es)
EC (1) ECSP10010208A (es)
ES (1) ES2432666T3 (es)
IL (1) IL205352A (es)
MX (1) MX2010004889A (es)
MY (1) MY154063A (es)
NI (1) NI201000076A (es)
PA (1) PA8801901A1 (es)
PE (1) PE20090951A1 (es)
PL (1) PL2214637T3 (es)
TW (1) TW200934531A (es)
UY (1) UY31444A1 (es)
WO (1) WO2009056980A1 (es)
ZA (1) ZA201003848B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
WO2011107855A2 (en) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
KR101897302B1 (ko) * 2010-04-30 2018-09-11 브리스톨-마이어스 스큅 컴퍼니 Ｎ－（４－（２－아미노－３－클로로피리딘－４－일옥시）－３－플루오로페닐）－４－에톡시－１－（４－플루오로페닐）－２－옥소－１，２－디히드로피리딘－３－카르복스아미드를 포함하는 제약 조성물
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
CN103966680A (zh) * 2014-05-04 2014-08-06 东华大学 一种药物缓释纳米纤维的制备方法
WO2016190638A1 (ko) * 2015-05-22 2016-12-01 에스케이바이오팜 주식회사 카리스바메이트를 포함하는 약제, 및 통증 또는 뇌전증을 예방, 경감 또는 치료하기 위한 그의 용도
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105997866B (zh) * 2016-07-13 2019-08-20 成都明慈医药科技有限公司 一种含地塞米松的混悬剂及其制备方法
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
KR102369827B1 (ko) 2020-09-04 2022-03-04 (주)피알지에스앤텍 프로게리닌을 포함하는 나노현탁액 및 이의 제조방법
US20220213802A1 (en) * 2021-01-06 2022-07-07 General Electric Company System for controlling blade clearances within a gas turbine engine
KR20230114478A (ko) 2022-01-25 2023-08-01 (주)피알지에스앤텍 프로게리닌을 포함하는 과립제 및 이를 이용한 샤셋제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265728A (en) 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
RU2141821C1 (ru) * 1994-10-14 1999-11-27 Жансен Фармасетика Н.В. Водная суспензия сабелюзола для орального применения и способ ее изготовления
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
HUP0203198A3 (en) 1999-08-20 2005-07-28 Ortho Mcneil Pharm Inc Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
RS50505B (sr) * 2001-02-27 2010-03-02 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju anksioznih poremećaja
WO2004110995A1 (en) * 2003-06-17 2004-12-23 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
EA200970378A1 (ru) * 2006-10-13 2009-10-30 Янссен Фармацевтика, Н. В. Композиции фенилалкилкарбамата
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate

Also Published As

Publication number Publication date
US20160008476A1 (en) 2016-01-14
WO2009056980A1 (en) 2009-05-07
EP2214637B1 (en) 2013-05-08
TW200934531A (en) 2009-08-16
ES2432666T3 (es) 2013-12-04
ZA201003848B (en) 2011-08-31
KR20100092944A (ko) 2010-08-23
PA8801901A1 (es) 2009-06-23
EA019881B1 (ru) 2014-07-30
MX2010004889A (es) 2010-05-19
BRPI0818118A2 (pt) 2015-08-04
AU2008320458B2 (en) 2014-01-23
JP2011500870A (ja) 2011-01-06
MY154063A (en) 2015-04-30
NI201000076A (es) 2010-11-10
CN101848699A (zh) 2010-09-29
KR101568681B1 (ko) 2015-11-12
BRPI0818118B8 (pt) 2021-05-25
PL2214637T3 (pl) 2013-10-31
JP2016216486A (ja) 2016-12-22
US9161913B2 (en) 2015-10-20
UY31444A1 (es) 2009-04-30
AU2008320458A1 (en) 2009-05-07
US20170112798A1 (en) 2017-04-27
JP6273589B2 (ja) 2018-02-07
US20120309826A1 (en) 2012-12-06
JP5841333B2 (ja) 2016-01-13
AR069125A1 (es) 2009-12-30
US8263652B2 (en) 2012-09-11
CA2703971C (en) 2017-10-10
CL2008003261A1 (es) 2009-10-16
US20090111872A1 (en) 2009-04-30
BRPI0818118B1 (pt) 2020-05-12
CN104840971A (zh) 2015-08-19
JP2014193913A (ja) 2014-10-09
CR11550A (es) 2011-01-14
EA201070534A1 (ru) 2010-12-30
ECSP10010208A (es) 2010-06-29
PE20090951A1 (es) 2009-07-13
US10201519B2 (en) 2019-02-12
CA2703971A1 (en) 2009-05-07
EP2214637A1 (en) 2010-08-11
IL205352A (en) 2014-09-30
IL205352A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
CO6270300A2 (es) Suspension pediatrica estabilizada de carisbamato
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
GT201300253A (es) Preparacion de gadobutrol de alta pureza
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
SMT201600065B (it) Procedimento per la produzione di composti di 177lu altamente puri senza supporto nonché composti di 177lu senza supporto
DOP2012000151A (es) Nuevos compuestos triciclicos
MX2011011374A (es) Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma.
CR10148A (es) Derivados de las benzamidas y heteroarenos
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
CU20110088A7 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
UY32822A (es) Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
UA107702C2 (en) Novel benzamide derivatives
CO6650398A2 (es) Compuestos y composición farmacéutica para el tratamiento de los transtornos asociados a los receptores 5-ht1a y 5.ht2a
MA35002B1 (fr) Forme cristalline delta du sel d'arginine du périndopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EA202090127A1 (ru) Новые применения чистого антагониста 5-htрецептора
CL2018000665A1 (es) Formas cristalinas
GT201500039A (es) Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad de reflujo
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
FA Application withdrawn